Table 3. PSA comparison of outcomes for intermediate-dose PQ informed by G6PD testing (100% access) compared to low-dose PQ used without G6PD testing, assuming 100% adherence to the allocated PQ regiment.
| G6PDd prevalence | Sex | Median change in no. SH events per 10,000 patients (10th– 90th percentiles) | Median change in no. recurrences per 10,000 patients (10th– 90th percentiles) | Percent of simulations (n = 10,000) | |||
|---|---|---|---|---|---|---|---|
| More SH; more recurrences | More SH; fewer recurrences | Fewer SH; more recurrences | Fewer SH; fewer recurrences | ||||
| 1% | Male | 13.9 (-10.9–37.4) | 82.1 (-140.6–305.0) | 53.7 | 24.1 | 14.7 | 7.6 |
| Female | 19.9 (-1.7–43.1) | 75.5 (-148.1–299.4) | 59.3 | 29.0 | 7.5 | 4.2 | |
| 5% | Male | -17.1 (-54.0–13.4) | 116.5 (-105.0–335.5) | 18.5 | 6.2 | 56.9 | 18.5 |
| Female | 12.9 (-11.6–37.1) | 82.6 (-140.0–305.2) | 53.0 | 23.7 | 15.7 | 7.7 | |
| 10% | Male | -56.5 (-108.3 –-16.2) | 158.1 (-60.3–374.5) | 2.8 | 0.5 | 80.0 | 16.7 |
| Female | 2.3 (-26.6–28.5) | 95.0 (-127.8–316.7) | 38.8 | 15.8 | 32.5 | 13.0 | |
SH: severe haemolysis